Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer

We performed a meta-analysis to comprehensively investigate the efficacy and safety of immune-checkpoint inhibitors (ICIs) plus chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). The primary outcome was overall survival (OS). The secondary outcomes included progression-f...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother Cancer
Päätekijät: Zhou, Fei, Zhao, Wencheng, Gong, Xiaomei, Ren, Shengxiang, Su, Chunxia, Jiang, Tao, Zhou, Caicun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2020
Aiheet:
Commentary
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7477983/
https://ncbi.nlm.nih.gov/pubmed/32900864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001300
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia